Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed EBITDA Margin for 11 consecutive years, with 12051.01% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 1830372.0% to 12051.01% in Q3 2025 year-over-year; TTM through Dec 2025 was 32564.25%, a 3236394.0% decrease, with the full-year FY2025 number at 32564.25%, down 3236191.0% from a year prior.
  • EBITDA Margin was 12051.01% for Q3 2025 at Cartesian Therapeutics, up from 5334.9% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 12051.01% in Q3 2025 to a low of 6252.71% in Q3 2024.
  • A 5-year average of 211.2% and a median of 38.35% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -611499bps in 2024, then skyrocketed 1830372bps in 2025.
  • Cartesian Therapeutics' EBITDA Margin stood at 40.86% in 2021, then dropped by -15bps to 34.92% in 2022, then plummeted by -6254bps to 2149.07% in 2023, then soared by 157bps to 1228.23% in 2024, then surged by 881bps to 12051.01% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's EBITDA Margin are 12051.01% (Q3 2025), 5334.9% (Q2 2025), and 4419.5% (Q1 2025).